4//SEC Filing
Nielsen Jack 4
Accession 0001104659-22-119223
CIK 0001802665other
Filed
Nov 14, 7:00 PM ET
Accepted
Nov 15, 6:26 PM ET
Size
10.7 KB
Accession
0001104659-22-119223
Insider Transaction Report
Form 4
Nielsen Jack
Director
Transactions
- Sale
Common Stock
2022-11-11$57.14/sh−36,800$2,102,752→ 3,013,461 total(indirect: See Footnote) - Sale
Common Stock
2022-11-14$58.70/sh−58,667$3,443,753→ 2,954,794 total(indirect: See Footnote) - Sale
Common Stock
2022-11-15$56.80/sh−62,933$3,574,594→ 2,891,861 total(indirect: See Footnote)
Footnotes (5)
- [F1]The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.
- [F2]The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2022.
- [F3]The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $55.89 to $58.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (3) to this Form 4.
- [F4]The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $56.82 to $59.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4.
- [F5]The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $55.91 to $61.22, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (5) to this Form 4.
Documents
Issuer
Harmony Biosciences Holdings, Inc.
CIK 0001802665
Entity typeother
Related Parties
1- filerCIK 0001602402
Filing Metadata
- Form type
- 4
- Filed
- Nov 14, 7:00 PM ET
- Accepted
- Nov 15, 6:26 PM ET
- Size
- 10.7 KB